{"id":107649,"date":"2025-08-30T10:42:14","date_gmt":"2025-08-30T10:42:14","guid":{"rendered":"https:\/\/www.newsbeep.com\/ca\/107649\/"},"modified":"2025-08-30T10:42:14","modified_gmt":"2025-08-30T10:42:14","slug":"a-gentler-take-on-the-glp-1-craze","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/ca\/107649\/","title":{"rendered":"a gentler take on the GLP-1 craze?"},"content":{"rendered":"<p>                    &#13;<br \/>\n&#13;<\/p>\n<p>On TV, in magazines and on social media: glucagon-like peptide 1 (GLP-1) agonist drugs such as Mounjaro, Wegovy and, especially, Ozempic are inescapable right now.<\/p>\n<p>&#13;<br \/>\n&#13;<\/p>\n<p>In just a few short years, they have profoundly altered the way we view weight management and metabolic wellness, generating billions of dollars in the process.1<\/p>\n<p>&#13;<br \/>\n&#13;<\/p>\n<p>But this is only part of the story. The more mainstream GLP-1 agonists become, the more concerns grow surrounding their side-effects, as well as questions about accessibility and long-term efficacy.2,3<\/p>\n<p>&#13;<br \/>\n&#13;<\/p>\n<p>So what does this all mean for nutraceutical producers? We\u2019ve already seen significant opportunities emerge for the development of \u201cGLP-1 companion products\u201d to soothe common symptoms and fill nutritional gaps, but could there be another way to tap into this undeniable demand?\u00a0<\/p>\n<p>                                    Not yet a Subscriber?<\/p>\n<p>\n                                        This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Nutraceutical Business Review.<\/p>\n<p>                                    <a href=\"https:\/\/hpcimedia.com\/service\/signup-campaign\/NBRSub\" class=\"btn\" rel=\"nofollow noopener\" target=\"_blank\">Subscribe now<\/a><br \/>\n                                    Already a subscriber? <a href=\"https:\/\/nutraceuticalbusinessreview.com\/authentication\" rel=\"nofollow noopener\" target=\"_blank\">Sign in here.<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"&#13; &#13; On TV, in magazines and on social media: glucagon-like peptide 1 (GLP-1) agonist drugs such as&hellip;\n","protected":false},"author":2,"featured_media":107650,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[36],"tags":[49,48,84,395],"class_list":{"0":"post-107649","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-nutrition","8":"tag-ca","9":"tag-canada","10":"tag-health","11":"tag-nutrition"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts\/107649","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/comments?post=107649"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts\/107649\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/media\/107650"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/media?parent=107649"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/categories?post=107649"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/tags?post=107649"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}